Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Natera, Inc.NTRA · Entity 2635 | PRESIDENT, CLINICALDIAGNOSTICS | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Natera, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 106,914 |
Ending reported balance
After 2026-10-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-10-01 · Sale · Disposed 200 · Balance 109,714 F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $411.55 to $411.69 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-10-01 · Sale · Disposed 954 · Balance 108,760 F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $412.8350 to $413.3100 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-10-01 · Sale · Disposed 1,846 · Balance 106,914 F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $414.44 to $415.19 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $411.55 to $411.69 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $412.8350 to $413.3100 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $414.44 to $415.19 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2024 Filed Mar 30, 2024 01:35 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 707 | $90.42 | $63,923.97 |
DisclosureSEC source: 0001415889-24-009475 · form4-03292024_090311.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,560 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on March 27, 2020. Read SEC document |
| March 05, 2024 Filed Mar 8, 2024 02:40 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 2,227 | $88.37 | $196,788.86 |
DisclosureSEC source: 0001415889-24-007243 · form4-03072024_090309.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,267 F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and in compliance with Rule 10b5-1. Read SEC document |
| March 05, 2024 Filed Mar 8, 2024 02:40 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 18 | $87.33 | $1,571.86 |
DisclosureSEC source: 0001415889-24-007243 · form4-03072024_090309.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,494 F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and in compliance with Rule 10b5-1. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.31 to $87.3415 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 01:45 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 2,329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-006194 · form4-03012024_080304.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,306 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs were fully-vested at the time of issuance. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 29, 2024 Filed Mar 8, 2024 02:40 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 3,206 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-007243 · form4-03072024_090309.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,512 F1 · shares: On June 10, 2022, the Reporting Person was granted performance-based Restricted Stock Units (the "RSUs") covering 12,826 shares of Common Stock vesting in tranches upon the Issuer achieving certain specified financial and operating metrics. On February 29, 2024, the achievement of milestones for the vesting of RSUs covering 3,206 shares of Common Stock was certified. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 02:02 UTC | Natera, Inc. NTRA · Entity 2635 | SaleCommon Stock | 3,426 | $65.09 | $223,002.11 |
DisclosureSEC source: 0001415889-24-002018 · form4-01312024_020131.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,977 F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and in compliance with Rule 10b5-1. Read SEC document |
| January 26, 2024 Filed Jan 31, 2024 02:02 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 31,352 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-002018 · form4-01312024_020131.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,403 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs vest over four years. 25% of the RSUs vest on January 26, 2025 and the remaining RSUs vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.